Daiichi Sankyo-Merck’s ‘guided-missile’ cancer drug meets main goal in late-stage trial

CAR-T Digest - August 2020

18 Sep 2024: Daiichi Sankyo-Merck’s ‘guided-missile’ cancer drug meets main goal in late-stage trial

Daiichi Sankyo and Merck announced that Patritumab Deruxtecan successfully extended progression-free survival in a late-stage study for non-small cell lung cancer (NSCLC)
The trial involved 586 patients with a specific gene mutation linked to abnormal cell growth, comparing the drug to chemotherapy
Patritumab deruxtecan is one of three antibody-drug conjugates in a joint development deal between Merck and Daiichi Sankyo worth up to $22 billion
The drug was tested on patients who had previously received tyrosine kinase inhibitors (TKIs), which target mutations causing unchecked cell growth
The companies plan to present trial data at an upcoming medical meeting and will share findings with regulatory authorities for further discussion